anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

27 Cost Of Inaction

Loop collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 31,900
Current window 22,021-22,050
Pages 1,064
Rows per page 30
Loop: 27 Cost Of Inactionclear collectionreset all
18 30 60

Loop

22,021-22,050 of 31,900

filter-aware
05
The slide uses a circular diagram to represent the AI-driven feedback loop between wet-lab data generation and model training.Absci | Investor Conference Presentation Deck | 22 slides · Absci
Conference presentation Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
06
The slide illustrates a process flow from target antigen to AI-designed antibodies.Absci | Investor Conference Presentation Deck | 22 slides · Absci
Conference presentation Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
16
Includes a medical illustration of brain pathways related to wakefulness and neurotransmitters.Alkermes | Investor Conference Presentation Deck | 29 slides · Alkermes
Conference presentation Investor relations Beat · ComplicationLoop · Cost Of Inaction1 hit
17
The chart is currently empty, serving as a framework template for future data plotting.Alkermes | Investor Conference Presentation Deck | 29 slides · Alkermes
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
18
Alkermes | Investor Conference Presentation Deck | 29 slidesAlkermes | Investor Conference Presentation Deck | 29 slides · Alkermes
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
19
The radar chart represents a multi-dimensional optimization framework for drug development.Alkermes | Investor Conference Presentation Deck | 29 slides · Alkermes
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
20
Alkermes | Investor Conference Presentation Deck | 29 slidesAlkermes | Investor Conference Presentation Deck | 29 slides · Alkermes
Conference presentation Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
21
The slide features a screenshot of a conference poster or presentation title slide.Alkermes | Investor Conference Presentation Deck | 29 slides · Alkermes
Conference presentation Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
22
Alkermes | Investor Conference Presentation Deck | 29 slidesAlkermes | Investor Conference Presentation Deck | 29 slides · Alkermes
Conference presentation Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
23
The slide outlines a standard clinical trial protocol structure.Alkermes | Investor Conference Presentation Deck | 29 slides · Alkermes
Conference presentation Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
24
Alkermes | Investor Conference Presentation Deck | 29 slidesAlkermes | Investor Conference Presentation Deck | 29 slides · Alkermes
Conference presentation Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
25
Alkermes | Investor Conference Presentation Deck | 29 slidesAlkermes | Investor Conference Presentation Deck | 29 slides · Alkermes
Conference presentation Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
07
The slide uses a map to show regional prevalence and a nested circle diagram to show the funnel from total infected to treated patients.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
15
AstraZeneca | Investor Conference Presentation Deck | 26 slidesAstraZeneca | Investor Conference Presentation Deck | 26 slides · AstraZeneca
Conference presentation Investor relations Beat · The BreakthroughLoop · Cost Of Inaction1 hit
16
The slide uses a waterfall-style growth diagram for Ultomiris and a combination of bar charts and bulleted metrics for HPP assets.AstraZeneca | Investor Conference Presentation Deck | 26 slides · AstraZeneca
Conference presentation Investor relations Beat · The BreakthroughLoop · Cost Of Inaction1 hit
17
The slide uses a split layout: left side details specific drug assets (anselamimab, ALXN2220) with clinical stage data, right side outlines the genomic medicine strategy.AstraZeneca | Investor Conference Presentation Deck | 26 slides · AstraZeneca
Conference presentation Investor relations Beat · The BreakthroughLoop · Cost Of Inaction1 hit
03
Slide 03 of the deck.ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
04
The slide uses a Gantt-style visualization to show drug development progress across Preclinical, Phase 1, Phase 2, and Phase 3 stages.ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
05
The slide uses a table-like structure to track progress (checkmarks for completed, squares for upcoming) across 8 distinct drug programs.ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
06
The slide uses a blue-tinted portrait to evoke a clinical or therapeutic context.ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
07
Includes two line charts showing PK and PD profiles across different dosage levels.ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
08
The slide outlines a 12-week open-label study with a specific focus on treatment-resistant depression (TRD).ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
09
The slide uses a timeline-based process diagram to illustrate the clinical trial flow.ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
10
The slide features a stylized portrait of a person, likely a patient or representative, within a circular frame.ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
11
Includes a map of global disease burden and key product features.ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
12
The slide cites a third-party study (Palhano-Fontes et al.) as proxy evidence for DMT efficacy.ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
13
The slide uses a process flow diagram to show the progression of the trial parts.ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
14
The slide uses a minimalist design with a focus on the product name and target indications, accompanied by a human-centric image.ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
15
The slide uses a line chart to show the change in MADRS scores over 12 weeks for three different dosages.ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
16
The slide outlines two distinct study designs (COMP 005 and COMP 006) with specific primary endpoints at week 6.ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit